Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011, Article ID 749653, 5 pages
http://dx.doi.org/10.4061/2011/749653
Clinical Study

Metformin-Associated Acute Kidney Injury and Lactic Acidosis

Nephrology Department, Hospital General Universitario Gregorio Marañón, Street Dr. Esquerdo 46, 28007 Madrid, Spain

Received 17 May 2011; Accepted 8 June 2011

Academic Editor: Alejandro Martín-Malo

Copyright © 2011 David Arroyo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy : aonsensus statement from the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetologia, vol. 52, no. 1, pp. 17–30, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter, “Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD002967, 2005. View at Publisher · View at Google Scholar · View at PubMed
  3. A. Seidowsky, S. Nseir, N. Houdret, and F. Fourrier, “Metformin-associated lactic acidosis: a prognostic and therapeutic study,” Critical Care Medicine, vol. 37, no. 7, pp. 2191–2196, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. N. Peters, N. Jay, D. Barraud et al., “Metformin-associated lactic acidosis in an intensive care unit,” Critical Care, vol. 12, no. 6, article no. R149, 2008. View at Publisher · View at Google Scholar · View at PubMed
  5. D. Heaney, A. Majid, and B. Junor, “Bicarbonate haemodialysis as a treatment of metformin overdose,” Nephrology Dialysis Transplantation, vol. 12, no. 5, pp. 1046–1047, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. G. C. Jones, J. P. Macklin, and W. D. Alexander, “Contraindications to the use of metformin,” British Medical Journal, vol. 326, no. 7379, pp. 4–5, 2003. View at Google Scholar · View at Scopus
  7. M. Stumvoll, N. Nurjhan, G. Perriello, G. Dailey, and J. E. Gerich, “Metabolic effects of metformin in non-insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 333, no. 9, pp. 550–554, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. R. Owen, E. Doran, and A. P. Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. J. A. Dykens, J. Jamieson, L. Marroquin, S. Nadanaciva, P. A. Billis, and Y. Will, “Biguanide-induced mitocondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro,” Toxicology and Applied Pharmacology, vol. 233, no. 2, pp. 203–210, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. K/DOQI Workgroup, “K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients,” American Journal of Kidney Diseases, vol. 45, no. 4, supplement 3, pp. S1–153, 2005. View at Google Scholar